Quarterly Report (10-q)

0000318299 false --04-30 Q3 P2Y P2Y P2Y P2Y P2Y P2Y 0000318299 2021-05-01 2022-01-31 0000318299 2022-03-16 0000318299 2022-01-31 0000318299 2021-04-30 0000318299 SRCO:SeriesAConvertiblePreferredStockMember 2022-01-31 0000318299 SRCO:SeriesAConvertiblePreferredStockMember 2021-04-30 0000318299 SRCO:SeriesBRedeemablePreferredStockMember 2022-01-31 0000318299 SRCO:SeriesBRedeemablePreferredStockMember 2021-04-30 0000318299 SRCO:SeriesCRedeemableConvertiblePreferredStockMember 2022-01-31 0000318299 SRCO:SeriesCRedeemableConvertiblePreferredStockMember 2021-04-30 0000318299 SRCO:SeriesDRedeemableConvertiblePreferredStockMember 2022-01-31 0000318299 SRCO:SeriesDRedeemableConvertiblePreferredStockMember 2021-04-30 0000318299 2021-11-01 2022-01-31 0000318299 2020-11-01 2021-01-31 0000318299 2020-05-01 2021-01-31 0000318299 SRCO:InformationTechnologyMember 2021-11-01 2022-01-31 0000318299 SRCO:InformationTechnologyMember 2020-11-01 2021-01-31 0000318299 SRCO:InformationTechnologyMember 2021-05-01 2022-01-31 0000318299 SRCO:InformationTechnologyMember 2020-05-01 2021-01-31 0000318299 SRCO:NewWorldHealthBrandsMember 2021-11-01 2022-01-31 0000318299 SRCO:NewWorldHealthBrandsMember 2020-11-01 2021-01-31 0000318299 SRCO:NewWorldHealthBrandsMember 2021-05-01 2022-01-31 0000318299 SRCO:NewWorldHealthBrandsMember 2020-05-01 2021-01-31 0000318299 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-04-30 0000318299 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2021-04-30 0000318299 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2021-04-30 0000318299 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2021-04-30 0000318299 us-gaap:CommonStockMember 2021-04-30 0000318299 SRCO:CommonStockToBeIssuedMember 2021-04-30 0000318299 us-gaap:AdditionalPaidInCapitalMember 2021-04-30 0000318299 us-gaap:RetainedEarningsMember 2021-04-30 0000318299 us-gaap:NoncontrollingInterestMember 2021-04-30 0000318299 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-05-01 2021-07-31 0000318299 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2021-05-01 2021-07-31 0000318299 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2021-05-01 2021-07-31 0000318299 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2021-05-01 2021-07-31 0000318299 us-gaap:CommonStockMember 2021-05-01 2021-07-31 0000318299 SRCO:CommonStockToBeIssuedMember 2021-05-01 2021-07-31 0000318299 us-gaap:AdditionalPaidInCapitalMember 2021-05-01 2021-07-31 0000318299 us-gaap:RetainedEarningsMember 2021-05-01 2021-07-31 0000318299 us-gaap:NoncontrollingInterestMember 2021-05-01 2021-07-31 0000318299 2021-05-01 2021-07-31 0000318299 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-07-31 0000318299 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2021-07-31 0000318299 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2021-07-31 0000318299 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2021-07-31 0000318299 us-gaap:CommonStockMember 2021-07-31 0000318299 SRCO:CommonStockToBeIssuedMember 2021-07-31 0000318299 us-gaap:AdditionalPaidInCapitalMember 2021-07-31 0000318299 us-gaap:RetainedEarningsMember 2021-07-31 0000318299 us-gaap:NoncontrollingInterestMember 2021-07-31 0000318299 2021-07-31 0000318299 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-08-01 2021-10-31 0000318299 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2021-08-01 2021-10-31 0000318299 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2021-08-01 2021-10-31 0000318299 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2021-08-01 2021-10-31 0000318299 us-gaap:CommonStockMember 2021-08-01 2021-10-31 0000318299 SRCO:CommonStockToBeIssuedMember 2021-08-01 2021-10-31 0000318299 us-gaap:AdditionalPaidInCapitalMember 2021-08-01 2021-10-31 0000318299 us-gaap:RetainedEarningsMember 2021-08-01 2021-10-31 0000318299 us-gaap:NoncontrollingInterestMember 2021-08-01 2021-10-31 0000318299 2021-08-01 2021-10-31 0000318299 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-10-31 0000318299 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2021-10-31 0000318299 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2021-10-31 0000318299 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2021-10-31 0000318299 us-gaap:CommonStockMember 2021-10-31 0000318299 SRCO:CommonStockToBeIssuedMember 2021-10-31 0000318299 us-gaap:AdditionalPaidInCapitalMember 2021-10-31 0000318299 us-gaap:RetainedEarningsMember 2021-10-31 0000318299 us-gaap:NoncontrollingInterestMember 2021-10-31 0000318299 2021-10-31 0000318299 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-11-01 2022-01-31 0000318299 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2021-11-01 2022-01-31 0000318299 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2021-11-01 2022-01-31 0000318299 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2021-11-01 2022-01-31 0000318299 us-gaap:CommonStockMember 2021-11-01 2022-01-31 0000318299 SRCO:CommonStockToBeIssuedMember 2021-11-01 2022-01-31 0000318299 us-gaap:AdditionalPaidInCapitalMember 2021-11-01 2022-01-31 0000318299 us-gaap:RetainedEarningsMember 2021-11-01 2022-01-31 0000318299 us-gaap:NoncontrollingInterestMember 2021-11-01 2022-01-31 0000318299 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-01-31 0000318299 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2022-01-31 0000318299 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2022-01-31 0000318299 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2022-01-31 0000318299 us-gaap:CommonStockMember 2022-01-31 0000318299 SRCO:CommonStockToBeIssuedMember 2022-01-31 0000318299 us-gaap:AdditionalPaidInCapitalMember 2022-01-31 0000318299 us-gaap:RetainedEarningsMember 2022-01-31 0000318299 us-gaap:NoncontrollingInterestMember 2022-01-31 0000318299 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-04-30 0000318299 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2020-04-30 0000318299 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2020-04-30 0000318299 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2020-04-30 0000318299 us-gaap:CommonStockMember 2020-04-30 0000318299 SRCO:CommonStockToBeIssuedMember 2020-04-30 0000318299 us-gaap:AdditionalPaidInCapitalMember 2020-04-30 0000318299 us-gaap:RetainedEarningsMember 2020-04-30 0000318299 us-gaap:NoncontrollingInterestMember 2020-04-30 0000318299 2020-04-30 0000318299 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-05-01 2020-07-31 0000318299 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2020-05-01 2020-07-31 0000318299 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2020-05-01 2020-07-31 0000318299 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2020-05-01 2020-07-31 0000318299 us-gaap:CommonStockMember 2020-05-01 2020-07-31 0000318299 SRCO:CommonStockToBeIssuedMember 2020-05-01 2020-07-31 0000318299 us-gaap:AdditionalPaidInCapitalMember 2020-05-01 2020-07-31 0000318299 us-gaap:RetainedEarningsMember 2020-05-01 2020-07-31 0000318299 us-gaap:NoncontrollingInterestMember 2020-05-01 2020-07-31 0000318299 2020-05-01 2020-07-31 0000318299 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-07-31 0000318299 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2020-07-31 0000318299 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2020-07-31 0000318299 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2020-07-31 0000318299 us-gaap:CommonStockMember 2020-07-31 0000318299 SRCO:CommonStockToBeIssuedMember 2020-07-31 0000318299 us-gaap:AdditionalPaidInCapitalMember 2020-07-31 0000318299 us-gaap:RetainedEarningsMember 2020-07-31 0000318299 us-gaap:NoncontrollingInterestMember 2020-07-31 0000318299 2020-07-31 0000318299 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-08-01 2020-10-31 0000318299 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2020-08-01 2020-10-31 0000318299 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2020-08-01 2020-10-31 0000318299 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2020-08-01 2020-10-31 0000318299 us-gaap:CommonStockMember 2020-08-01 2020-10-31 0000318299 SRCO:CommonStockToBeIssuedMember 2020-08-01 2020-10-31 0000318299 us-gaap:AdditionalPaidInCapitalMember 2020-08-01 2020-10-31 0000318299 us-gaap:RetainedEarningsMember 2020-08-01 2020-10-31 0000318299 us-gaap:NoncontrollingInterestMember 2020-08-01 2020-10-31 0000318299 2020-08-01 2020-10-31 0000318299 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-10-31 0000318299 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2020-10-31 0000318299 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2020-10-31 0000318299 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2020-10-31 0000318299 us-gaap:CommonStockMember 2020-10-31 0000318299 SRCO:CommonStockToBeIssuedMember 2020-10-31 0000318299 us-gaap:AdditionalPaidInCapitalMember 2020-10-31 0000318299 us-gaap:RetainedEarningsMember 2020-10-31 0000318299 us-gaap:NoncontrollingInterestMember 2020-10-31 0000318299 2020-10-31 0000318299 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-11-01 2021-01-31 0000318299 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2020-11-01 2021-01-31 0000318299 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2020-11-01 2021-01-31 0000318299 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2020-11-01 2021-01-31 0000318299 us-gaap:CommonStockMember 2020-11-01 2021-01-31 0000318299 SRCO:CommonStockToBeIssuedMember 2020-11-01 2021-01-31 0000318299 us-gaap:AdditionalPaidInCapitalMember 2020-11-01 2021-01-31 0000318299 us-gaap:RetainedEarningsMember 2020-11-01 2021-01-31 0000318299 us-gaap:NoncontrollingInterestMember 2020-11-01 2021-01-31 0000318299 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-01-31 0000318299 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2021-01-31 0000318299 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2021-01-31 0000318299 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2021-01-31 0000318299 us-gaap:CommonStockMember 2021-01-31 0000318299 SRCO:CommonStockToBeIssuedMember 2021-01-31 0000318299 us-gaap:AdditionalPaidInCapitalMember 2021-01-31 0000318299 us-gaap:RetainedEarningsMember 2021-01-31 0000318299 us-gaap:NoncontrollingInterestMember 2021-01-31 0000318299 2021-01-31 0000318299 SRCO:SharesToBeIssuedMember 2021-05-01 2022-01-31 0000318299 SRCO:NotesConvertibleAtHoldersOptionMember 2022-01-31 0000318299 SRCO:NotesConvertibleAtHoldersOptionMember 2021-04-30 0000318299 SRCO:NotesConvertibleAtCompanysOptionMember 2022-01-31 0000318299 SRCO:NotesConvertibleAtCompanysOptionMember 2021-04-30 0000318299 SRCO:NonConvertibleNotesPayableMember 2022-01-31 0000318299 SRCO:NonConvertibleNotesPayableMember 2021-04-30 0000318299 srt:MinimumMember 2021-05-01 2022-01-31 0000318299 srt:MaximumMember 2021-05-01 2022-01-31 0000318299 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2022-01-31 0000318299 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MaximumMember 2022-01-31 0000318299 us-gaap:MeasurementInputPriceVolatilityMember srt:MinimumMember 2022-01-31 0000318299 us-gaap:MeasurementInputPriceVolatilityMember srt:MaximumMember 2022-01-31 0000318299 us-gaap:MeasurementInputExpectedTermMember srt:MinimumMember 2021-05-01 2022-01-31 0000318299 us-gaap:MeasurementInputExpectedTermMember srt:MaximumMember 2021-05-01 2022-01-31 0000318299 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2021-04-30 0000318299 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MaximumMember 2021-04-30 0000318299 us-gaap:MeasurementInputPriceVolatilityMember srt:MinimumMember 2021-04-30 0000318299 us-gaap:MeasurementInputPriceVolatilityMember srt:MaximumMember 2021-04-30 0000318299 us-gaap:MeasurementInputExpectedDividendRateMember 2021-04-30 0000318299 us-gaap:MeasurementInputExpectedTermMember srt:MinimumMember 2020-05-01 2021-04-30 0000318299 us-gaap:MeasurementInputExpectedTermMember srt:MaximumMember 2020-05-01 2021-04-30 0000318299 us-gaap:SeriesBPreferredStockMember 2022-01-31 0000318299 us-gaap:SeriesCPreferredStockMember 2022-01-31 0000318299 us-gaap:SeriesDPreferredStockMember 2022-01-31 0000318299 us-gaap:SeriesCPreferredStockMember 2021-05-01 2022-01-31 0000318299 us-gaap:CommonStockMember us-gaap:SeriesCPreferredStockMember 2021-05-01 2022-01-31 0000318299 us-gaap:SeriesDPreferredStockMember 2021-05-01 2022-01-31 0000318299 us-gaap:CommonStockMember us-gaap:SeriesDPreferredStockMember 2021-05-01 2022-01-31 0000318299 SRCO:SeriesCConvertiblePreferredStockMember 2020-05-01 2021-01-31 0000318299 SRCO:SeriesCConvertiblePreferredStockMember 2020-05-01 2020-10-31 0000318299 SRCO:SeriesCConvertiblePreferredStockMember 2021-01-31 0000318299 SRCO:SeriesDConvertiblePreferredStockMember SRCO:SettlementOfAccountsPayableMember 2020-05-01 2021-01-31 0000318299 SRCO:SeriesDConvertiblePreferredStockMember SRCO:SettlementOfAccountsPayableMember 2021-01-31 0000318299 SRCO:SeriesDConvertiblePreferredStockMember 2020-05-01 2021-01-31 0000318299 SRCO:SeriesDConvertiblePreferredStockMember 2021-01-31 0000318299 us-gaap:CommonStockMember SRCO:FourAccreditedInvestorsMember 2021-05-01 2022-01-31 0000318299 us-gaap:CommonStockMember SRCO:FourAccreditedInvestorsMember 2022-01-31 0000318299 SRCO:SeriesCConvertiblePreferredStockMember us-gaap:CommonStockMember 2020-08-01 2020-10-31 0000318299 us-gaap:CommonStockMember SRCO:SeriesCConvertiblePreferredStockMember 2020-10-31 0000318299 us-gaap:CommonStockMember SRCO:SeriesDConvertiblePreferredStockMember SRCO:SettlementOfAccountsPayableMember 2020-08-01 2020-10-31 0000318299 us-gaap:CommonStockMember SRCO:SeriesDConvertiblePreferredStockMember SRCO:SettlementOfAccountsPayableMember 2020-10-31 0000318299 us-gaap:CommonStockMember SRCO:SeriesDConvertiblePreferredStockMember 2020-08-01 2020-10-31 0000318299 us-gaap:CommonStockMember SRCO:SeriesDConvertiblePreferredStockMember 2020-10-31 0000318299 us-gaap:CommonStockMember SRCO:SeriesDConvertiblePreferredStockOneMember 2020-10-31 0000318299 SRCO:HavensStockOptionAgreementMember us-gaap:CommonStockMember 2021-05-01 2022-01-31 0000318299 SRCO:AhmanStockOptionAgreementMember us-gaap:CommonStockMember 2021-05-01 2022-01-31 0000318299 us-gaap:CommonStockMember SRCO:TwoIndependentDirectorMember 2022-01-02 2022-01-03 0000318299 us-gaap:CommonStockMember SRCO:TwoIndependentDirectorMember 2022-01-03 0000318299 SRCO:ChiefExecutiveOfficerAndVicePresidentMember us-gaap:CommonStockMember 2022-01-02 2022-01-03 0000318299 SRCO:ChiefExecutiveOfficerAndVicePresidentMember us-gaap:CommonStockMember 2022-01-03 0000318299 SRCO:FourEmployeesMember us-gaap:CommonStockMember 2022-01-02 2022-01-03 0000318299 SRCO:FourEmployeesMember us-gaap:CommonStockMember 2022-01-03 0000318299 SRCO:BoardOfDirectorsMember 2020-12-29 2020-12-30 0000318299 us-gaap:FairValueInputsLevel1Member 2022-01-31 0000318299 us-gaap:FairValueInputsLevel2Member 2022-01-31 0000318299 us-gaap:FairValueInputsLevel3Member 2022-01-31 0000318299 us-gaap:FairValueInputsLevel1Member 2021-04-30 0000318299 us-gaap:FairValueInputsLevel2Member 2021-04-30 0000318299 us-gaap:FairValueInputsLevel3Member 2021-04-30 0000318299 SRCO:ExecutiveOfficeSpaceMember 2021-05-01 2022-01-31 0000318299 SRCO:LenderOneMember 2022-01-31 0000318299 SRCO:LenderTwoMember 2022-01-31 0000318299 SRCO:NewYorkCountyKingsMember 2016-09-21 2016-09-22 0000318299 SRCO:PromissoryNoteMember 2015-02-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended January 31, 2022

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE EXCHANGE ACT

For the transition period from ________ to ___________.

Commission file number: 0-9483

SPARTA COMMERCIAL SERVICES, INC.

(Exact name of registrant as specified in its charter)

Nevada		30-0298178
(State or other jurisdiction of		(IRS Employer
incorporation or organization)		Identification No.)

555 Fifth Avenue, 14th Floor, New York, NY 10017

(Address of principal executive offices) (Zip Code)

(212) 239-2666

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common stock, $.001 par value		SRCO		Pink Open Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 504 of Regulation S-T (§229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to file such files). ☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☐	Smaller reporting company ☒
(Do not check if a smaller reporting company)	Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No

As of March 16, 2022, we had 14,903,005 shares of common stock issued and outstanding.

SPARTA COMMERCIAL SERVICES, INC.

FORM 10-Q

FOR THE QUARTER ENDED January 31, 2022

TABLE OF CONTENTS

		Page

PART I.	FINANCIAL INFORMATION

Item 1.	Financial Statements (Unaudited)	3

	Condensed Consolidated Balance Sheets as of January 31, 2022 (unaudited) and April 30, 2021	3
	Condensed Consolidated Statements of Operations for the Nine Months Ended January 31, 2022 and 2021 (unaudited)	4
	Condensed Consolidated Statement of Changes in Deficit for the Three and Nine Months ended January 31, 2022 (unaudited)	5
	Condensed Consolidated Statements of Cash Flows for the Nine Months Ended January 31, 2022 and 2021 (unaudited)	6
	Notes to Unaudited Condensed Consolidated Financial Statements	7

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	16

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	21

Item 4.	Controls and Procedures	21

PART II.	OTHER INFORMATION

Item 1.	Legal Proceedings	22

Item 1A.	Risk Factors	22

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	23

Item 3.	Defaults Upon Senior Securities	23

Item 5.	Other Information	23

Item 6.	Exhibits	23

Signatures		24

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

SPARTA COMMERCIAL

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)

	January 31, 2022			April 30, 2021

ASSETS
Current Assets
Cash and cash equivalents	$	30,711		$	396
Accounts receivable		2,742			469
Inventory		9,979			13,823
Total Current Assets		43,432			14,688
Property and equipment, net of accumulated depreciation and amortization of $213,262 and $212,905, respectively		-			-
Other assets		9,628			9,628
Deposits		9,000			9,000
Total assets	$	62,060		$	33,316
LIABILITIES AND DEFICIT
Liabilities:
Current Liabilities
Bank overdraft	$	49,667		$	49,041
Accounts payable and accrued expenses		3,528,414			3,627,831
Short Term Loan		141,585			409,013
Current portion notes payable		5,230,084			4,680,275
Deferred revenue		5,514			13,946
Derivative liabilities		8,288,379			3,446,738
Total Current Liabilities		17,243,643			12,226,844
Loans payable-related parties		432,403			432,403
Total Long Term Liabilities		432,403			432,403
Total liabilities	$	17,676,046		$	12,659,247
Deficit:
Preferred stock, $0.001 par value; 10,000,000 shares authorized of which 35,850 shares have been designated as Series A convertible preferred stock, with a stated value of $100 per share, 125 and 125 shares issued and outstanding, respectively		12,500			12,500
Preferred stock B, 1,000 shares have been designated as Series B redeemable preferred stock, $0.001 par value, with a liquidation and redemption value of $10,000 per share, 57 and 0 shares issued and outstanding, respectively		-			-
Preferred stock C, 4,200,000 shares have been designated as Series C redeemable, convertible preferred, $0.001 par value, with a liquidation and redemption value of $10 per share, 2,163,000 and 4,132,269 shares issued and outstanding, respectively		2,363			4,145
Preferred stock D, 2,000,000 shares have been designated as Series D redeemable, convertible preferred, $0.001 par value, with a liquidation and redemption value of $1.00 per share, 618,411 and 1,493,962 shares issued and outstanding, respectively		618			1,494
Preferred stock value
Common stock, $0.001 par value; 750,000,000 shares authorized, and 14,253,005 and 9,809,877 shares issued and outstanding as of January 31 and April 30, 2021 respectively		14,473			9,810
Common stock to be issued 2,349,697 and 1,215,000, respectively		23,438			1,215
Additional paid-in-capital		52,827,502			51,351,156
Accumulated deficit		(71,466,089	)		(64,993,250	)
Total deficiency in stockholders’ deficit		(18,585,195	)		(13,612,930	)
Non-controlling interest		971,209			986,999
Total Deficit		(17,613,986	)		(12,625,931	)
Total Liabilities and Deficit	$	62,060		$	33,316

See accompanying notes to unaudited condensed consolidated financial statements.

SPARTA COMMERCIAL

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (Unaudited)


	Three Months Ended January 31,						Nine Months Ended January 31
	2022			2021			2022			2021
Revenue
Information technology	$	112,691		$	49,220		$	168,933		$	185,001
New World Health Brands		8,714			4,253			18,170			10,026
Total Revenue		121,405			53,473			187,103			195,027
Less Cost of goods sold		19,435			7,504			32,551			53,238
Gross profit	$	101,970		$	45,969		$	154,552		$	141,789
Operating expenses:
General and administrative		590,304			229,407			847,017			1,163,116
Depreciation and amortization		-			-			-			-
Total operating expenses	$	590,304		$	229,407		$	847,017		$	1,163,116
Loss from operations	$	(488,334	)	$	(183,438	)	$	(692,465	)	$	(1,021,327	)
Other (income) expense:
Other income	$	(3,297	)	$	(5,944	)	$	(11,356	)	$	(6,694	)
Forgiveness of debt		-			(62,277	)		-			(125,330	)
Financing cost		180,750			4,688			180,750			300,417
Amortization of debt discount					-
Loss (gain) in changes in fair value of derivative liability		1,062,260			0			5,990,400			1,310,307
Total other (income) expense	$	1,239,713		$	(63,533	)	$	6,159,794		$	1,478,700
Income (loss) from continuing operations		(1,728,047	)		(119,905	)		(6,488,628	)		(2,500,027	)
Loss from discontinued operations		-			-			-			-
Net income (loss)		(1,728,047	)		(119,905	)		(6,852,259	)		(2,500,027	)
Net loss attributed to non-controlling interest		15,479			(903	)		15,790			(6,837	)
Preferred dividend		-			-			(382	)		(191	)
Net income (loss) attributed to common stockholders	$	(1,743,526	)	$	(120,808	)	$	(6,836,851	)	$	(2,507,055	)

Basic and diluted loss per share:
Loss from continuing operations attributable to Sparta Commercial Services, Inc. common stockholders		(0.13	)		(0.02	)		0.55			(0.40	)
Loss from discontinued operations attributable to Sparta Commercial Services, Inc. common stockholders		-			-			-			-
Net loss attributable to Sparta Commercial Services, Inc. common stockholders	$	(0.10	)	$	(0.02	)	$	0.54		$	(0.40	)

Weighted average shares outstanding		13,265,570			7,094,502			12,568,827			6,270,929

See accompanying notes to unaudited condensed consolidated financial statements.

SPARTA COMMERCIAL

CONDENSED CONSOLIDATED STATEMENTS OF DEFICIT (Unaudited)

As January 31, 2022 and 2021


	Series A Preferred Stock				Series B Preferred Stock				Series C Preferred Stock						Series D Preferred Stock						Common Stock						Common Stock to be issued						Additional Paid in			Accumulated			Non- controlling
	Shares		Amount		Shares		Amount		Shares			Amount			Shares			Amount			Shares			Amount			Shares			Amount			Capital			Deficit			Interest			Total
Balance April 30, 2021		125	$	12,500		-	$	-		4,132,269		$	4,145			1,493,962		$	1,494			9,809,877		$	9,810			1,214,528		$	1,215		$	51,351,156			(64,993,250	)	$	986,999			(12,625,931	)
Issuance of preferred shares
Issuance of preferred shares, shares
Issuane of common shares
Issuane of common shares, shares
Preferred dividend
Preferred dividend, shares
Preferred dividends
Sale of preferred stock
Sale of preferred stock, shares
Sale of common stock
Sale of common stock, shares
Stock based compensation
Shares issued for settlement of accounts payable
Shares issued for settlement of accounts payable, shares
Option issued for settlement of accounts payable
Shares issued for conversion of subsidiary preferred
Shares issued for conversion of subsidiary preferred,shares
Shares to be issued
Shares to be issued, shares
Sale of common stock
Sale of common stock, shares
Shares cancelled due to reverse split
Shares cancelled due to reverse split, shares
Shares re-issue for stock split
Shares re-issue for stock split, shares
Conversion of preferred shares
Conversion of preferred shares, shares
Issuance of shares for services
Issuance of shares for services , shares
Conversion of Preferred to common stocks										(704,300	)		(704	)		(302,551	)		(303	)		1,574,001			1,574									373,326									373,893
Conversion of notes to common shares																						125,000			125									24,875									25,000
Common shares issued for cash																												1,134,697			1,135			98,183									99,318
Net loss		-		-		-		-		-			-			-			-			-			-			-			-			-			379,802			338			380,140
Balance July 31, 2021		125	$	12,500		-	$	-		3,427,969		$	3,441			1,191,411		$	1,191			11,508,878		$	11,509			2,349,225		$	2,350		$	51,847,540		$	(64,613,448	)	$	987,337		$	(11,747,580	)
Issuance of preferred shares										(281,000	)		(281	)		(409,000	)		(409	)								(2,349,225	)		(2,350	)		(317,979	)								(321,019	)
Issuance of common shares																						696,475			696			22,442,105			22,443			(22,443	)								696
Preferred dividend																																					(382	)					(382	)
Net loss for the quarter end October 31,2021		-		-		-		-																													(5,124,212	)		311			(5,123,901	)
Balances October 31, 2021		125	$	12,500		-	$	-		3,146,969		$	3,160			782,411		$	782			12,205,353		$	12,205			22,442,105		$	22,443		$	51,507,118		$	(69,738,042	)	$	987,648		$	(17,192,186	)
Conversion of preferred shares										(983,969	)		(797	)		(164,000	)		(164	)		1,620,417			1,841			995,500			995			1,295,321						(960	)	$	1,296,236
Issuance of shares for services																						427,235			427								$	25,063									25,490
Net loss		-		-		-		-		-			-			-			-			-			-			-			-			-		$	(1,728,047	)	$	(15,479	)	$	(1,613,986	)
Balances January 31, 2022		-	$	12,500		-	$	-		2,163,000		$	2,363			618,411		$	618			14,253,005		$	14,473			23,437,605		$	23,438		$	52,827,502		$	(71,466,089	)	$	971,209		$	(17,613,986	)

Balance April 30, 2020		125	$	12,500		-	$	-		4,005		$	4,005			1,132		$	1,132			6,270,929		$	627,093			84,786,511		$	84,787		$	49,406,954			(62,702,339	)	$	974,251			(11,591,617	)
Sale of preferred stock										140			140																					69,860									70,000
Sale of common stock																						133,333			13,333									6,667									20,000
Stock based compensation																																		464,718									464,718
Shares issued for settlement of accounts payable																311			311															311,067									311,378
Option issued for settlement of accounts payable																																		156,947									156,947
Shares issued for conversion of subsidiary preferred																51			51															(40	)					(11	)		-
Preferred dividend																																					(191	)					(191	)
Net loss		-		-		-		-																				-			-						(2,216,867	)		1,972			(2,214,895	)
Balance July 31, 2020		125	$	12,500		-	$	-		4,145		$	4,145			1,494		$	1,494			6,404,262		$	640,426			84,786,511		$	84,787		$	50,416,173		$	(64,919,397	)	$	976,212		$	(12,783,660	)
Sale of preferred stocks										10			10			102			102																								112
Shares issued for conversion of subsidiary preferred																						66,700,000		$	66,700								$	(38,098	)	$	2,163						30,765
Preferred dividends																												23,333,000		$	23,333												23,333
Net loss for the quarter end October 31, 2021		-		-		-		-																												$	(165,227	)	$	(7,895	)		(173,122	)
Balance October 31, 2020		125	$	12,500		-	$	-		4,155		$	4,155			1,596		$	1,596			73,104,262		$	707,126			108,119,511		$	108,120		$	50,378,075		$	(65,082,461	)	$	968,317		$	(12,902,572	)
Beginning Balance		125	$	12,500		-	$	-		4,155		$	4,155			1,596		$	1,596			73,104,262		$	707,126			108,119,511		$	108,120		$	50,378,075		$	(65,082,461	)	$	968,317		$	(12,902,572	)
Sale of preferred stock				26									19																														45
Shares to be issued																												555,000		$	55,000		$	53,000									108,000
Sale of common stock																						15,000,000			15,000								$	169,245					$	6,837			191,082
Shares cancelled due to reverse split																						(88,104,262	)		(722,126	)		(108,674,511	)	$	(108,175	)											(830,301	)
Shares re-issue for stock split																						7,094,758			709,476			1,220,078		$	44,571												754,047
Net loss		-		-		-		-		-			-			-			-																	$	(119,905	)	$	(903	)		(120,808	)
Balances January 31, 2021		125	$	12,526		-	$	-		4,155		$	4,174			1,596		$	1,596			7,094,758		$	709,476			1,220,078		$	99,516		$	50,600,320		$	(65,202,366	)	$	974,251		$	(12,800,507	)
Ending Balance		125	$	12,526		-	$	-		4,155		$	4,174			1,596		$	1,596			7,094,758		$	709,476			1,220,078		$	99,516		$	50,600,320		$	(65,202,366	)	$	974,251		$	(12,800,507	)

See accompanying notes to unaudited condensed consolidated financial statements.

SPARTA COMMERCIAL

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)


	Nine Months Ended January 31,
	2022			2021

CASH FLOWS FROM OPERATING ACTIVITIES
Net Income (loss)	$	(6,852,259	)	$	(2,500,027	)
Adjustments to reconcile net loss to net cash used in operating activities:
Adjustment on Preferred Stock A		-
Stock based compensation		262,466			464,718
Loss (Gain) from change in fair value of derivative liabilities		5,990,400			1,450,321
Amortization of debt discount		40,000			-
Non-cash financing cost		180,750			300,417
Non-cash consulting fees		90,448
Forgiveness of debt /adjustments		(190,186	)		(212,049	)
Changes in operating assets and liabilities
Accounts receivable		(2,273	)		(14,701	)
Inventory		3,844			4,644
Other assets		-			(1,637	)
Accounts payable and accrued expenses		15,736			(399,452	)
Deferred revenue		(8,432	)		9,005
Net cash from (used) operating activities		(469,506	)		(898,761	)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of equipment		-			-
Net cash (used in) investing activities		-			-
CASH FLOWS FROM FINANCING ACTIVITIES
Bank overdraft		(626	)		(10,486	)
Proceeds from sale of stock		407,500			526,002
Proceeds from notes payable		-			191,085
Payments on notes payable		(267,428	)		-
Proceeds from related party notes		-			-
Payments on related party notes					219,928
Conversion of promissory notes		359,123
Net cash provided by financing activities		499,821			926,529

Net (decrease) increase in cash	$	30,315		$	27,768

Cash and cash equivalents, beginning of period	$	396			-
Cash and cash equivalents , end of period	$	30,711		$	27,768

Cash paid for:
Interest				$	-
Income taxes	$	-		$	-

See accompanying notes to unaudited condensed consolidated financial statements.

SPARTA COMMERCIAL SERVICES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JANUARY 31, 2022 AND APRIL 30, 2021 (UNAUDITED)

NOTE A – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

A summary of the significant accounting policies applied in the preparation of the accompanying unaudited condensed consolidated financial statements follows.

Business

Sparta Commercial Services, Inc. (“Sparta,” “we,” “us,” or the “Company”) is a Nevada corporation with headquarters in New York City, www.spartacommercial.com. We are a multi-disciplined parent corporation operating across three business sectors – Financial Services, E-Commerce & Mobile Technology, and Health and Wellness, (www.spartacommercial.com).

Sparta’s roots are in the Powersports industry. The Company provided retail installment loans and leases through authorized motorcycle dealerships in 33 states, with financing provided by institutional lenders. The Company also maintained a full underwriting and servicing platform for its portfolio. Notwithstanding the discontinuance of our initial focus on consumer loans and leases post Lehman and during the 2008 financial crisis; in 2007, the Company had introduced a new initiative, Municipal Financing, (www.spartamunicipal.com), which has financed over 100 jurisdictions to date. Sparta’s Municipal Finance program is also currently available to all nonprofit organizations which adhere to IRS guidelines, including 501(c)3 of the Internal Revenue Code.

Vehicle History Reports are a staple of Sparta’s E-Commerce Technology subsidiary iMobile Solutions, Inc. Whether a vehicle is intended for business or recreational use, Sparta’s Vehicle History Reports are highly regarded for accuracy and completeness and have been sold across all 50 states and in 62 countries worldwide. They provide a trusted layer of assurance to vehicle buyers and are available on Kelley Blue Book, Auto Trader, AllState Insurance and a range of various dealership websites. They include Cyclechex (Motorcycle History Reports at www.cyclechex.com), RVchex (Recreational Vehicle History Reports at www.rvchex.com), CarVINreport (Automobile History Reports at www.carvinreport.com), and Truckchex (Heavy Duty Truck History Reports at www.truckchex.com).

Sparta’s response to the onset of the COVID 19 pandemic in early 2020 quickly took shape with thorough investigations into evolving customer trends in health and wellness. As a result, we expanded New World Health Brands and developed a new product line of natural dietary supplements. In August 2020, we launched an online B to C website: www.newworldhealthbrands.com, featuring high quality dietary supplements, including vitamins and minerals, such as, Zinc, Magnesium, Boron, Iodine, Beetroot Extract, Selenium, Vitamin B Complex, Vitamin C and PQQ. To ensure the safety and quality of our products, all health and wellness offerings are exclusively sourced and manufactured in the United States and adhere to strict U.S. standards and guidelines. Sparta’s commitment to high standards and transparency are tantamount to being a trusted brand.

Sparta’s newest subsidiary, Sparta Crypto, Inc., was established September 25, 2020 and is in the process of completing a proprietary state-of-the-art platform designed to connect users of widely adopted digital currencies with sellers of various goods and services. The platform has not launched and the Company can make no assurances that the described plan will reach implementation. In addition, the Company has completed and tested a cryptocurrency payment gateway called SpartaPayIQ, which is functional and was formally announced on March 3, 2022.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements as of January 31, 2022 and for the three and nine months periods ended January 31, 2022 and 2020 have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission, including Form 10-Q and Regulation S-K. The information furnished herein reflects all adjustments (consisting of normal recurring accruals and adjustments), which are, in the opinion of management, necessary to fairly present the operating results for the respective periods. Certain information and footnote disclosures normally present in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to such rules and regulations. The Company believes that the disclosures provided are adequate to make the information presented not misleading.

These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and explanatory notes for the year ended April 30, 2021 as disclosed in the Company’s Form 10-K for that year as filed with the Securities and Exchange Commission. The results of operations for the nine months ended January 31, 2022 are not necessarily indicative of the results to be expected for any other interim period or the full year ending April 30, 2022.

The condensed consolidated balance sheet as of April 30, 2021 contained herein has been derived from the audited consolidated financial statements as of April 30, 2021, but do not include all disclosures required by the U.S. GAAP.

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its majority owned subsidiaries. All material intercompany transactions and balances have been eliminated in consolidation. The third-party ownership of the Company’s subsidiary is accounted for as noncontrolling interest in the consolidated financial statements. Changes in the noncontrolling interest are reported in the statement of changes in deficit.

Estimates

These financial statements have been prepared in accordance with accounting principles generally accepted in United States of America which require management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosures of revenues and expenses for the reported period. Accordingly, actual results could differ from those estimates. Included in these estimates are assumptions about collection of accounts receivable, useful life of property and equipment, beneficial conversion feature of convertible notes payable, deferred income tax asset valuation allowances, and valuation of derivative liabilities.

Revenue Recognition

During the first quarter of 2018, the Company adopted ASU 2014-09, Revenue from Contracts with Customers (Topic 606), using the cumulative-effect method. The new standard requires an entity to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The adoption did not have an impact in our consolidated financial statements, other than the enhancement of our disclosures related to our revenue-generating activities. The Company acts as a principal in its revenue transactions as the Company is the primary obligor in the transactions.

Revenues from mobile app products and New World Health products are generally recognized upon delivery. Revenues from history reports are generally recognized upon delivery / download. Prepayments received from customers before delivery (if any) are recognized as deferred revenue and recognized upon delivery.

Cash Equivalents

For the purpose of the accompanying unaudited condensed consolidated financial statements, all highly liquid investments with an original maturity of three months or less are considered to be cash equivalents.

Website Development Costs

The Company recognizes website development costs in accordance with ASC 350-50, “Accounting for Website Development Costs.” As such, the Company expenses all costs incurred that relate to the planning and post implementation phases of development of its website. Direct costs incurred in the development phase are capitalized and recognized over the estimated useful life. Costs associated with repair or maintenance for the website are included in cost of net revenues in the current period expenses.

Fair Value Measurements

The Company has adopted ASC 820, “Fair Value Measurements (“ASC 820”).” ASC 820 establishes a three-level fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets the lowest priority to unobservable inputs to fair value measurements of certain assets and Liabilities. The three levels of the fair value hierarchy under ASC 820 are described below:

●	Level 1 — Quoted prices for identical instruments in active markets. Level 1 assets and liabilities include debt and equity securities and derivative contracts that are traded in an active exchange market, as well as certain securities that are highly liquid and are actively traded in over-the-counter markets.

●	Level 2 — Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model derived valuations in which all significant inputs and significant value drivers are observable in active markets.

●	Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value measurements. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques based on significant unobservable inputs, as well as management judgments or estimates that are significant to valuation.

This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. For some products or in certain market conditions, observable inputs may not always be available.

Income Taxes

We utilize ASC 740 “Income Taxes” which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at year-end based on enacted laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income.

The Company recognizes the impact of a tax position in the financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Our practice is to recognize interest and/or penalties related to income tax matters in income tax expense.

Stock Based Compensation

We account for our stock-based compensation under ASC 718 “Compensation – Stock Compensation” using the fair value based method. Under this method, compensation cost is measured at the grant date based on the value of the award and is recognized over the service period, which is usually the vesting period. This guidance establishes standards for the accounting for transactions in which an entity exchanges it equity instruments for goods or services. It also addresses transactions in which an entity incurs liabilities in exchange for goods or services that are based on the fair value of the entity’s equity instruments or that may be settled by the issuance of those equity instruments.

We use the fair value method for equity instruments granted to non-employees and use the Black-Scholes model for measuring the fair value of options. The stock based fair value compensation is determined as of the date of the grant or the date at which the performance of the services is completed (measurement date) and is recognized over the vesting periods.

Inventories

The Company’s inventories represent finished goods, consist of products available for sale and are accounted for using the first-in, first-out (FIFO) method and valued at the lower of cost or net realizable value. Inventory consists of finished goods for the Company’s New World Health business.

Concentrations of Credit Risk

Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents and receivables. The Company places its cash and temporary cash investments with high credit quality institutions. At times, such investments may be in excess of the FDIC insurance limit.

Net Loss Per Share

The Company uses ASC 260-10, “Earnings Per Share” for calculating the basic and diluted loss per share. The Company computes basic loss per share by dividing net loss and net loss attributable to common shareholders by the weighted average number of common shares outstanding. Common equivalent shares are excluded from the computation of net loss per share if their effect is anti-dilutive.

As of January 31, 2022, 133,278,980 shares potential shares (including 12,205,353 shares to be issued on the balance sheet), were excluded from the shares used to calculate diluted earnings per share as their inclusion would reduce net loss per share.

Derivative Liabilities

The Company assessed the classification of its derivative financial instruments as of January 31, 2022 and April 30, 2021, which consist of convertible instruments and rights to shares of the Company’s common stock and determined that such derivatives meet the criteria for liability classification under ASC 815.

ASC 815 generally provides three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as freestanding derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument subject to the requirements of ASC 815. ASC 815 also provides an exception to this rule when the host instrument is deemed to be conventional, as described.

Convertible Instruments

The Company evaluates and accounts for conversion options embedded in its convertible instruments in accordance with professional standards for “Accounting for Derivative Instruments and Hedging Activities”.

The Company accounts for convertible instruments (when it has determined that the embedded conversion options should not be bifurcated from their host instruments) in accordance with professional standards when “Accounting for Convertible Securities with Beneficial Conversion Features,” as those professional standards pertain to “Certain Convertible Instruments.” Accordingly, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their earliest date of redemption. The Company also records when necessary deemed dividends for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. ASC 815-40 provides that, among other things, generally, if an event is not within the entity’s control could or require net cash settlement, then the contract shall be classified as an asset or a liability.

Reclassifications

Certain reclassifications have been made to conform to prior periods’ data to the current presentation. These reclassifications had no effect on reported losses.

Recent Accounting Pronouncements-

In February 2016, the FASB issued Accounting Standards Update No. 2016-02 (Topic 842) “Leases.” Topic 842 supersedes the lease requirements in Accounting Standards Codification (ASC) Topic 840, “Leases.” Under Topic 842, lessees are required to recognize assets and liabilities on the balance sheet for most leases and provide enhanced disclosures. Leases will continue to be classified as either finance or operating. The Company adopted Topic 842 effective May 1, 2019 using a modified retrospective method and will not restate comparative periods. Adoption of this ASU did not have a material impact on the Company’s consolidated financial statements.

A variety of proposed or otherwise potential accounting standards are currently under study by standard setting organizations and various regulatory agencies. Due to the tentative and preliminary nature of those proposed standards, we have not determined whether implementation of such proposed standards would be material to our unaudited condensed consolidated financial statements.

NOTE B – GOING CONCERN MATTERS

The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying unaudited condensed consolidated financial statements, the Company has incurred recurring losses and generated negative cash flows from operating activities since inception. As of January 31, 2022, the Company had an accumulated deficit of $71,466,089 and a working capital deficit of $64,993,250. The Company’s cash balance and revenues generated are not currently sufficient and cannot be projected to cover its operating expenses for the next twelve months from the filing date of this report. These factors among others raise substantial doubt about the Company’s ability to continue as a going concern for a reasonable period of time.

The Company’s existence is dependent upon management’s ability to develop profitable operations. Management is devoting substantially all of its efforts to developing its business and raising capital and there can be no assurance that the Company’s efforts will be successful. No assurance can be given that management’s actions will result in profitable operations or the resolution of its liquidity problems. The accompanying unaudited condensed consolidated financial statements do not include any adjustments that might result should the Company be unable to continue as a going concern.

In order to improve the Company’s liquidity, the Company’s management is actively pursuing additional equity financing through discussions with investment bankers and private investors. There can be no assurance that the Company will be successful in its effort to secure additional equity financing.

NOTE C – NOTES PAYABLE AND DERIVATIVES

The Company has outstanding numerous notes payable to various parties. The notes bear interest at rates of 5% - 20% per year and are summarized as follows:

SCHEDULE OF NOTES PAYABLE

Notes Payable	January 31, 2022		April 30, 2021
Notes convertible at holder’s option	$	2,980,848	$	2,522,925
Notes convertible at Company’s option		335,700		335,700
Non-convertible notes payable		1,913,536		1,821,650
Subtotal		5,230,084		4,680,275
Debt discount		-		-
Total	$	5,230,084	$	4,680,275

Certain of the notes payable contain variable conversion rates and the conversion features are classified as derivative liabilities. The conversion prices are based on the market price of the Company’s common stock, at discounts of 30% - 48% to market value.

The Company’s derivative financial instruments consist of embedded derivatives related to the outstanding short term Convertible Notes Payable. These embedded derivatives include certain conversion features indexed to the Company’s common stock. The accounting treatment of derivative financial instruments requires that the Company record the derivatives and related items at their fair values as of the inception date of the Convertible Notes Payable and at fair value as of each subsequent balance sheet date. In addition, under the provisions of Accounting Standards Codification subtopic 815-40, Derivatives and Hedging; Contracts in Entity’s Own Equity (“ASC 815-40”), as a result of entering into the Convertible Notes Payable, the Company is required to classify all other non-employee stock options and warrants as derivative liabilities and mark them to market at each reporting date. Any change in fair value inclusive of modifications of terms will be recorded as non-operating, non-cash income or expense at each reporting date. If the fair value of the derivatives is higher at the subsequent balance sheet date, the Company will record a non-operating, non-cash charge. If the fair value of the derivatives is lower at the subsequent balance sheet date, the Company will record non-operating, non-cash income.

The change in fair value of the derivative liabilities at January 31, 2022, was calculated with the following average assumptions, using a Black-Scholes option pricing model are as follows:

Significant Assumptions:

Risk free interest rate	Ranging from	0.09 to 0.2	%
Expected stock price volatility	Ranging from	155 to 270	%
Expected dividend payout
Expected life in years	Ranging from	0.25 to 3.0 Years

The change in fair value of the derivative liabilities of convertible notes outstanding at April 30, 2021 was calculated with the following average assumptions, using a Black-Scholes option-pricing model are as follows:

Significant Assumptions:

Risk free interest rate	Ranging from	1.83% to 2.00	%
Expected stock price volatility		118% to 187	%
Expected dividend payout		0	%
Expected life in years	Ranging from	0.25 year to 2.0 years

During the nine months ended January 31, 2022 and 2021, the Company recorded a net loss of $6,852,259 and $2,507,055, respectively, related to the mainly due to change in value of the derivative liabilities.

Changes in derivative liability during the nine months ended January 31, 2022, and 2021 were:


	January 31,
	2021			2021
Balance, beginning of year	$	3,446,738		$	2,802,125
Derivative liability extinguished		(1,297,041	)		-
Derivative financial liability arising on the issuance of convertible notes and warrants					140,014
Fair value adjustments		6,138,682			1,310,307
Balance, end of period	$	8,288,379		$	4,252,446

NOTE D – LOANS PAYABLE TO RELATED PARTIES

As of January 31, 2022, and April 30, 2021, aggregated loans and notes payable, without demand and with no interest, to officers and directors were $432,403 and $432,403, respectively.

NOTE E – EQUITY TRANSACTIONS

Preferred Stock

The Company is authorized to issue 10,000,000 shares of preferred stock with $0.001 par value per share, of which 35,850 shares have been designated as Series A convertible preferred stock with a $100 stated value per share; 1,000 shares have been designated as Series B Preferred Stock with a $10,000 per share liquidation value; 4,200,000 shares have been designated as Series C Preferred Stock with a $10 per share liquidation value, and 2,000,000 shares have been designated as Series D Preferred Stock with a $1 per share liquidation value.

During the nine months ended January 31, 2022, the Company:

	●	Converted total of 1,969,269 preferred shares C to common shares valued at $373,893

	●	Converted a total of 3,194,418 preferred shares D to common shares valued at $975,217

During the nine months ended January 31, 2021, the Company:

	●	Sold 150 Units Series C Convertible Preferred stock for $70,000. Each Unit consists of 1 share of Series C Preferred stock (convertible at any time into 300 shares of the Company’s common stock) and 150 two-year Warrants to purchase one share of the Company’s common stock at $0.005 per share.
	●	Issued 311 Units Series D Convertible Preferred stock in settlement of $311,378 in accounts payable. Each Unit consists of 1 share of Series D Preferred stock (convertible at any time into 400 shares of the Company’s common stock) and 150 two-year Warrants to purchase one share of the Company’s common stock at $0.01 per share.
	●	Issued 51 Units Series D Convertible Preferred stock upon conversion of $51,000 of the Company’s subsidiary’ preferred stock. Each Unit consists of 1 share of Series D Preferred stock (convertible at any time into 400 shares of the Company’s common stock) and 150 two-year Warrants to purchase one share of the Company’s common stock at $0.01 per share.

Common Stock

The Company had 14,253,005 and 9,809,877 shares of common stock (after stock split effect) issued and outstanding as of January 31, 2022 and April 30, 2021, respectively. The Company had 2,349,697 and 1,215,000 shares (after stock split effect) of common classified as to be issued at January 31, 2022 and April 30, 2021.

During the nine months ended January 31, 2022, the Company:

	●	Issued 427,235 common shares for services valued at $25,063.
	●	Sold to four accredited investors 1,134,697 shares of common stock for cash of $70,000 and notes payable and accrued expenses settlement of $29,317.81 actual shares were not issued yet and recorded as commons stocks to be issued.
	●	Sold 140 Units Series C Convertible Preferred stock for $70,000. Each Unit consists of 1 share of Series C Preferred stock (convertible at any time into 3 shares of the Company’s common stock) and 1.5 two-year Warrants to purchase one share of the Company’s common stock at $0.050 per share.
	●	Issued 311 Units Series D Convertible Preferred stock in settlement of $311,378 in accounts payable. Each Unit consists of 1 share of Series D Preferred stock (convertible at any time into 4 shares of the Company’s common stock) and 1.5 two-year Warrants to purchase one share of the Company’s common stock at $1.00 per share.
	●	Issued 51 Units Series D Convertible Preferred stock upon conversion of $51,000 of the Company’s subsidiary’ preferred stock. Each Unit consists of 1 share of Series D Preferred stock (convertible at any time into 4 shares of the Company’s common stock) and 1.5 two-year Warrants to purchase one share of the Company’s common stock at $1.00 per share.
	●	On January 3, 2022, entered into agreements with Anthony L. Havens, the Company’s Chief Executive Officer (“Havens”) and Sandra L. Ahman, the Company’s Vice-President of Operations (“Ahman”) whereby Havens and Ahman agreed to convert debt owed to them in exchange for non-qualified stock options.
	●	Havens agreed to convert $137,465.76 of deferred salary in exchange for a stock option agreement (the “Havens Stock Option Agreement”) to purchase 1,718,322 shares of the Company’s common stock.
	●	Ahman agreed to convert $125,000 of deferred salary in exchange for a stock option agreement (the “Ahman Stock Option Agreement” and with the Havens Stock Option Agreement, the “Stock Option Agreements”) to purchase 1,562,500 shares of the Company’s common stock.
	●	On January 3, 2022, the Company granted to each of its two independent Directors five year options to purchase 187,500 shares of the Company’s common stock at $0.08 per share. The options vest in three equal tranches over three years. These options represent compensation for past service on the board.
	●	On January 3, 2022, the Company granted its CEO, Anthony L Havens and Vice President of Operations, Sandra L Ahman, five year options to purchase an aggregate of 750,000 shares of the Company’s common stock at $0.08 per share. The options vest in three equal tranches over three years.
	●	On January 3, 2022, the Company granted to four employees, five year options to purchase an aggregate of 437,500 shares of the Company’s common stock at $0.08 per share. The options vest in three equal tranches over three years.

During the nine months period ended January 31, 2021, the company

On December 30, 2020, filed with the Secretary of State of the state of Nevada, a Certificate of Amendment to its Articles of Incorporation (the “Amendment”), attached herewith as Exhibit 3.1, and incorporated by reference. The Amendment will be effective as of December 30, 2020. On July 9, 2020, the Board of Directors of the Company declared July 30, 2020 as the effective date for the 1 for 100 reverse stock split (the “Reverse Stock Split”), previously approved by the stockholders of the Company by written consent in accordance with the information contained in the Schedule 14C Information Statement filed with the Securities and Exchange Commission on July 9, 2020. FINRA reviewed and authorized the corporate action changing the effective date to December 30, 2020 (the “Effective Date”).

As a result of the Reverse Stock Split, for every one hundred shares of outstanding common stock will automatically be converted into one shares of the Company’s common stock immediately prior to the opening of trading on the next business day after the Effective Date. If, as a result of the reverse split, a stockholder is left with a fractional share, that stockholder shall receive one full share in lieu of such fractional share. Immediately after the effectiveness of the reverse split, there will be 7,027,930 shares of the Company’s common stock issued and outstanding. The aggregate number of shares of common stock that the Company is authorized to issue remains the same and was unaffected by the Reverse Stock Split. All outstanding stock options and other contractual rights including the preferred stock entitling the holders of such rights to acquire shares of common stock outstanding at the Effective Date will be appropriately adjusted to give effect to the Reverse Stock Split.

NOTE F – FAIR VALUE MEASUREMENTS

The Company follows the guidance established pursuant to ASC 820 which established a framework for measuring fair value and expands disclosure about fair value measurements. ASC 820 defines fair value as the amount that would be received for an asset or paid to transfer a liability (i.e., an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes the following three levels of inputs that may be used:

Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets and liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2: Observable prices that are based on inputs not quoted on active markets but corroborated by market data.

Level 3: Unobservable inputs when there is little or no market data available, thereby requiring an entity to develop its own assumptions. The fair value hierarchy gives the lowest priority to Level 3 inputs.

The table below summarizes the fair values of financial liabilities as of January 31, 2022:

	Fair Value at		Fair Value Measurement Using
	January 31, 2022		Level 1		Level 2		Level 3
Derivative liabilities	$	8,288,379		-		-	$	8,288,379

Fair values of financial liabilities as of April 30, 2021 are as follows:

	Fair Value at		Fair Value Measurement Using
	April 30, 2021		Level 1		Level 2		Level 3
Derivative liabilities	$	3,446,738		-		-	$	3,446,738

The following is a description of the valuation methodologies used for these items:

Derivative liabilities — these instruments consist of certain variable conversion features related to notes payable obligations and certain outstanding warrants. These instruments were valued using pricing models which incorporate the Company’s stock price, volatility, U.S. risk free rate, dividend rate and estimated life.

The Company did not identify any other non-recurring assets and liabilities that are required to be presented in the balance sheets at fair value in accordance with ASC Topic 825 “The Fair Value Option for Financial Issuances”.

NOTE G – COMMITMENTS AND CONTINGENCIES

In response to the COVID-19 pandemic, the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”) was signed into law in March 2020. The CARES Act lifts certain deduction limitations originally imposed by the Tax Cuts and Jobs Act of 2017 (“2017 Tax Act”). Corporate taxpayers may carryback net operating losses (NOLs) originating between 2018 and 2020 for up to five years, which was not previously allowed under the 2017 Tax Act. The CARES Act also eliminates the 80% of taxable income limitations by allowing corporate entities to fully utilize NOL carry forwards to offset taxable income in 2018, 2019 or 2020. Taxpayers may generally deduct interest up to the sum of 50% of adjusted taxable income plus business interest income (30% limit under the 2017 Tax Act) for 2019 and 2020. The CARES Act allows taxpayers with alternative minimum tax credits to claim a refund in 2020 for the entire amount of the credits instead of recovering the credits through refunds over a period of years, as originally enacted by the 2017 Tax Act.

In addition, the CARES Act raises the corporate charitable deduction limit to 25% of taxable income and makes qualified improvement property generally eligible for 15-year cost-recovery and 100% bonus depreciation. The enactment of the CARES Act did not result in any material adjustments to our income tax provision.

Operating Lease Commitments

Our executive offices are located in New York, NY. We have an agreement for use of office space at this location under a sub-lease which expired on October 31, 2019 and continues on a month-to-month basis thereafter. The monthly base rent is $5,100.

Rent expense was $43,200 and $48,600 for the nine months periods ended January 31, 2022 and 2021, respectively.

Litigation

The Company is subject to legal proceedings and claims which arise in the ordinary course of its business. Sparta can make no representations about the potential outcome of such proceedings.

As of January 31, 2022, we were not a party to any material pending legal proceeding except as stated below. From time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business.

The Company has received notices dated April 1, 2016, May 13, 2016 and July 22, 2016 from two lenders claiming defaults relating to conversion requests of $8,365 principal and $643 interest and $5,000 principal, with regard to notes in the total amounts of $55,125 and $27,500, respectively, which the Company has refused to process and believes it has defenses in that regard. These liabilities have been recorded in the unaudited condensed consolidated financial statements. While, there is no absolute guarantee in the outcome of litigation, should any be instituted, the Company believes the claim has no merit based on, among other things, a recent favorable decision by the New York State Court of Appeals relating to the affirmative defenses that would be raised on the Company’s behalf.

On September 22, 2016, a motion for summary judgment in lieu of complaint was filed in the Supreme Court of The State of New York County of Kings, against the Company by a lender seeking: damages in the amount of $102,170.82 in principal and interest; accrued and unpaid interest thereupon in the amount from the date of filing to entry of judgment herein; lender’s reasonable attorney’s fees, costs, and expenses; and any such other relief as the Court deems just and proper. Plaintiff’s motion for summary judgment in lieu of complaint was denied on May 5, 2017. On August 22, 2018, Plaintiff brought a second motion seeking summary judgment on the issue of liability which was denied on March 14, 2019. The Court found that there existed issues of fact warranting a trial. The most recent appearance in this matter was scheduled for March 13, 2020 at which time the Court marked the case “adjourned without a date” due to the restrictions imposed on the Courts from the COVID-19 pandemic. These liabilities have been recorded in the unaudited condensed consolidated financial statements. While, there is no absolute guarantee in the outcome of this litigation, the Company believes the claim has no merit based on, among other things, a recent favorable decision by the New York State Court of Appeals relating to the affirmative defenses raised on the Company’s behalf in this litigation.

On October 26, 2018, a lender commenced an action in the Supreme Court of the State of New York in New York County alleging damages from unpaid principal and interest, attorney’s fees, costs, and expenses arising from a promissory note dated February 26, 2015, in the amount of $50,000.00. Upon the completion of all discovery, a motion for summary judgment and cross motion to dismiss were fully submitted on September 15, 2021. At this time, the motions remain pending and we are awaiting a decision from the court. These liabilities have been recorded in the unaudited condensed consolidated financial statements. While, there is no absolute guarantee in the outcome of this litigation, the Company believes the claim has no merit based on, among other things, a recent favorable decision by the New York State Court of Appeals relating to the affirmative defenses raised on the Company’s behalf in this litigation.

NOTE H – SUBSEQUENT EVENTS

The Company has evaluated subsequent events for recognition and disclosure as of March 17, 2022 which is the date the financial statements were available to be issued. No other matters were identified affecting the accompanying financial statements and related disclosures.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

General

The following discussion of our financial condition and results of operations should be read in conjunction with (1) our interim unaudited condensed consolidated financial statements and their explanatory notes included as part of this quarterly report, and (2) our annual audited consolidated financial statements and explanatory notes for the year ended April 30, 2021 as disclosed in our annual report on Form 10-K for that year as filed with the SEC.

“Forward-Looking” Information

This report on Form 10-Q contains various statements that may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Rule 175 promulgated thereunder, Section 21E of the Securities Exchange Act of 1934, as amended, and Rule 3b-6 promulgated thereunder which represent our expectations and beliefs, including, but not limited to statements concerning the Company’s business and financial plans and prospects and are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” and other similar expressions can, but not always, identify forward-looking statements, which speak only as of the date such statement was made. We base these forward-looking statements on our current expectations and projections about future events, our assumptions regarding these events and our knowledge of facts at the time the statements are made. These statements by their nature involve substantial risks and uncertainties, certain of which are beyond our control, and actual results may differ materially depending on a variety of important factors. Risks and uncertainties that could cause our financial performance to differ materially from our goals, plans, expectations and projections expressed in forward-looking statements include those set forth in our filings with the Securities and Exchange Commission (“SEC”), including Item 1A of the Company’s Annual Report of Form 10-K for the year ended April 30, 2021. Forward-looking statements speak only as of the date they are made. The Company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made or to reflect the occurrence of unanticipated events. You should consider any forward-looking statements in light of this explanation, and we caution you about relying on forward-looking statements.

General Overview

Sparta’s roots are in the Powersports industry. The Company provided retail installment loans and leases through authorized motorcycle dealerships in 33 states, with financing provided by institutional lenders. The Company also maintained a full underwriting and servicing platform for its portfolio. Notwithstanding the discontinuance of our initial focus on consumer loans and leases post Lehman and during the 2008 financial crisis; in 2007, the Company had introduced a new initiative, Municipal Financing, (www.spartamunicipal.com), which has financed over 100 jurisdictions to date. Sparta’s Municipal Finance program is also currently available to all nonprofit organizations, institutions and entities. All nonprofit organizations which adhere to IRS guidelines, including 501 (c) 3 of the Internal Revenue Code, are eligible. Both public nonprofits, also known as public charities supported with publicly collected funds, and private nonprofits, also known as private foundations supported by an individual or business entity, qualify for the program.

The Company’s E-Commerce and Mobile Technology subsidiary name change to iMobile Solutions, Inc., from Specialty Reports, Inc., in 2017, signifies its ever-broadening service offerings in the evolving technology landscape. Under iMobile App (www.imobileapp.com), the Company provides mobile technology services, including web and mobile application creation, development and management for a wide range of businesses in the achievement of their marketing goals. Our ever-broadening business base of mobile application includes vehicle dealerships and racetracks, private clubs and country clubs, schools and entertainment venues, restaurants and grocery stores, as well as various other merchant types. (www.imobileapp.com/app-gallery). The Company also designs, launches, maintains and hosts websites for businesses. We provide specific, tailored action plans for our clients’ websites that include services such as eCommerce, CRM (Customer Relationship Management) development and integration, ordering system creation and integration, SEO (search engine optimization), social media marketing, and online reviews to improve their presence online. Additionally, we offer text messaging services, which supplement business marketing strategies both to gain and retain brand loyalty among its clients, customers and investors. Our text messaging platform allows our clients to easily manage, schedule and analyze text message performance.

Sparta created its subsidiary, New World Health Brands, Inc., in April 2019, on the heels of the Agriculture Improvement Act (also known as the Farm Bill), which was signed into law the previous December 20, 2018. Consequently, hemp (CBD) was removed from Schedule 1 of the Controlled Substances Act. Company management recognized the substantial business opportunity that lay ahead in the rapidly expanding hemp-CBD (cannabidiol) market in the United States. During 2019-2020, we sourced, developed and tested 5 CBD product categories totalling 31 products. We procured premium, domestic-grade, full-spectrum, broad-spectrum, and THC free hemp, created product packaging and labelling, and implemented fulfilment to launch an online B to C website: www.newworldhealthcbd.com on December 21, 2019. Our CBD products are available in full spectrum, broad spectrum and non-detectable below the legal limit of .3 THC (ND-THC) and come in capsules, oils, tablets, gel caps, tinctures, salves, creams, lotions, as well as pet tinctures. We remain watchful of consumer needs, adjusting our product line offerings either by adding new products, adjusting the potency levels of existing products or discontinuing still others, as warranted. To ensure the safety and quality of our products, all CBD product offerings are exclusively sourced, manufactured and tested at highly accredited testing facilities in the United States and adhere to strict U.S standards and guidelines. Because of our high standards, in-depth quality testing and label transparency, consumers know they can trust us.

Sparta’s response to the onset of the COVID 19 pandemic in early 2020 quickly took shape with thorough investigations into evolving customer trends in health and wellness. As a result, we expanded New World Health Brands and developed a new product line of natural dietary supplements. In August 2020, we launched an online B to C website: www.newworldhealthbrands.com, featuring high quality dietary supplements, including vitamins and minerals, such as, Zinc, Magnesium, Boron, Iodine, Beetroot Extract, Selenium, Vitamin B Complex, Vitamin C and PQQ. To ensure the safety and quality of our products, all health and wellness offerings are exclusively sourced and manufactured in the United States and adhere to strict U.S standards and guidelines. Sparta’s commitment to high standards and transparency are tantamount to being a trusted brand.

RESULTS OF OPERATIONS

Comparison of the nine Months Ended January 31, 2022 and 2021

For the nine months ended January 31, 2022, and 2021, we have generated Net losses of $6,473,220 and 2,507,055 respectively.

Revenues

Revenues totaled $187,103 during the nine months ended January 31, 2022, as compared to $195,027 during the nine months ended January 31, 2021, a decrease of $7,924 or 4%, primarily due to revenues from our Information Technology products declined by $16,068 or 9% offset by increase in our New World health revenues $8,144 or 81%. Our New World Health Brands continue to have positive results compared to the previous period primarily due to management efforts in marketing and promoting the products.

Cost of Revenue

Cost of revenue consists of costs and fees incurred to third parties to construct and maintain mobile apps, as well as fees for subscription services related to vehicle history reports and cost of goods purchased for New World Health Brand products. Cost of revenue was $32,551 during the nine months ended January 31, 2022, as compared to $5 during the nine months ended October 31, 2020. This $53,238 or 39% decline was due to New World Health Brands product line inventory purchases during the nine months period ending January 31, 2021.

Operating Expenses

General and administrative expenses were $847,017 during the nine months ended January 31, 2022, compared to $1,163,116 during the nine months ended January 31, 2021, a decrease of $316,099 or 27%, primarily due to the non-cash Black Scholes $464,718 valuation of options issued to management and directors in the previous period.

Expenses incurred during the current nine months period consisted primarily of the following expenses:

	January 31, 2022		January 31, 2021
Compensation, option and related cost		452,011		902,650
Accounting, audit and professional fees		50,642		86,461
Consulting Fees		142,884		2,500
Rent and Utilities		67,058		52,814
General office expenses		134,422		118,691
		847,017		1,163,116

Other (income) expense

Other (income) expense is comprised primarily of interest and financing costs $180,750 and related to the net change in fair value of our derivative liabilities $5,796,163 for the nine months ended January 31, 2022, compared to net other loss of 1,478,700 for the nine months ended January 31, 2021. The increase results were primarily from the change in the fair value of our derivative liabilities.

Net income (loss)

Our net loss attributable to common stockholders for the nine months ended January 31, 2022, $6,488,628 compared to loss of $2,500,027 primarily due to loss in valuation of derivative liabilities incurred as of January 31, 2022 of $5,626,769 while in the nine months period January 31, 2021 loss in valuation of derivative liabilities was $1,310,307.

LIQUIDITY AND CAPITAL RESOURCES

As of January 31, 2022, we had an accumulated deficit of $71,466,089 and a net loss for the nine months of $6,488,628. We generated a deficit in cash flow from operations of $469,506 for the nine months ended January 31, 2022. This deficit results primarily from our net loss of $6,488,628, offset by noncash expense of $352,914, amortization of debt discount $40,000, non-cash financing cost $180,750 and loss in fair value valuation of derivative liabilities $5,626,769 and an increase of $251,611 in accounts payables and accrued expenses.

We met our cash requirements during the period through proceeds from the sale of stock $407,500 and bank overdraft $29,442.

We do not anticipate incurring significant research and development expenditures, and we do not anticipate the sale or acquisition of any significant property, plant or equipment, during the next twelve months. At January 31, 2022, we had 6 full time employees. If we fully implement our business plan, we anticipate our employment base may increase during the next twelve months. As we continue to expand, we will incur additional cost for personnel. This potential increase in personnel is dependent upon our generating increased revenues and obtaining sources of financing. There is no guarantee that we will be successful in raising the funds required or generating revenues sufficient to fund the potential increase in the number of employees. Our employees are not represented by a union.

While we have raised capital to meet our working capital and financing needs in the past, additional financing is required in order to meet our current and potential future cash flow deficits from operations.

We continue to seek additional financing, which may be in the form of senior debt, subordinated debt or equity. We currently have no commitments for financing that are not at the investor’s election. There is no guarantee that we will be successful in raising the funds required to support our operations.

We estimate that we will need approximately $1,000,000 in addition to our normal operating cash flow to conduct operations during the next twelve months. However, there can be no assurance that additional private or public financing, including debt or equity financing, will be available as needed, or, if available, on terms favorable to us. Any additional equity financing may be dilutive to stockholders and such additional equity securities may have rights, preferences or privileges that are senior to those of our existing common or preferred stock. Furthermore, debt financing, if available, will require payment of interest and may involve restrictive covenants that could impose limitations on our operating flexibility. However, if we are not successful in generating sufficient liquidity from operations or in raising sufficient capital resources, on terms acceptable to us, this could have a material adverse effect on our business, results of operations, liquidity and financial condition, and we will have to adjust our planned operations and development on a more limited scale.

The effect of inflation on our revenue and operating results was not significant. Our operations are located in North America and there are no seasonal aspects that would have a material effect on our financial condition or results of operations.

GOING CONCERN ISSUES

The Company’s historical losses and the lack of revenues raise substantial doubts about the Company’s ability to continue as a going concern. If we are unable to develop our business, we have to discontinue operations or cease to exist, which would be detrimental to the value of the Company’s common stock. We can make no assurances that our business operations will develop and provide us with significant cash to continue operations.

In order to improve the Company’s liquidity, the Company’s management is actively pursuing additional financing through discussions with investment bankers, financial institutions and private investors. There can be no assurance the Company will be successful in its effort to secure additional financing.

We continue to experience net operating losses. Our ability to continue as a going concern is subject to our ability to develop profitable operations. We are devoting substantially all of our efforts to developing our business and raising capital. Our net operating losses increase the difficulty in meeting such goals and there can be no assurances that such methods will prove successful.

The primary issues management will focus on in the immediate future to address this matter include: seeking additional credit facilities from institutional lenders; seeking institutional investors for debt or equity investments in our Company; short term interim debt financing: and private placements of debt and equity securities with accredited investors.

To address these issues, we have engaged a financial advisory firm to advise and assist us in negotiating and raising capital.

INFLATION

The impact of inflation on the costs of the Company, and the ability to pass on cost increases to its customers over time is dependent upon market conditions. The Company is not aware of any inflationary pressures that have had any significant impact on the Company’s operations over the past quarter, and the Company does not anticipate that inflationary factors will have a significant impact on future operations.

OFF-BALANCE SHEET ARRANGEMENTS

The Company does not maintain off-balance sheet arrangements, nor does it participate in non-exchange traded contracts requiring fair value accounting treatment.

CRITICAL ACCOUNTING POLICIES

The preparation of our financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and judgments that affect our reported assets, liabilities, revenues, and expenses, and the disclosure of contingent assets and liabilities. We base our estimates and judgments on historical experience and on various other assumptions, we believe to be reasonable under the circumstances. Future events, however, may differ markedly from our current expectations and assumptions. While there are a number of significant accounting policies affecting our financial statements, we believe the following critical accounting policy involves the most complex, difficult and subjective estimates and judgments.

Revenue Recognition

Information Technology:

During the first quarter of 2019, the Company adopted ASU 2014-09, Revenue from Contracts with Customers (Topic 606), using the cumulative-effect method. The new standard requires an entity to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The adoption did not have an impact in our consolidated financial statements, other than the enhancement of our disclosures related to our revenue-generating activities. The Company acts as a principal in its revenue transactions as the Company is the primary obligor in the transactions.

Revenues from mobile app products are generally recognized upon delivery. Revenues from History Reports are generally recognized upon delivery / download. Prepayments received from customers before delivery (if any) are recognized as deferred revenue and recognized upon delivery.

New World Health Brands (“NWHB”):

Revenues from NWHB products are generally recognized upon delivery.

Stock-Based Compensation

The Company adopted Financial Accounting Standards Board Accounting Standard Codification Topic 718 (“ASC 718-10”), which records compensation expense on a straight-line basis, generally over the explicit service period of three to five years.

ASC 718-10 requires companies to estimate the fair value of share-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company’s Consolidated Statement of Operations. The Company is using the Black-Scholes option-pricing model as its method of valuation for share-based awards. The Company’s determination of fair value of share-based payment awards on the date of grant using an option-pricing model is affected by the Company’s stock price as well as assumptions regarding a number of highly complex and subjective variables. These variables include but are not limited to the Company’s expected stock price volatility over the term of the awards, and certain other market variables such as the risk-free interest rate.

Convertible Instruments

The Company accounts for convertible instruments (when it has determined that the embedded conversion options should not be bifurcated from their host instruments) in accordance with professional standards when “Accounting for Convertible Securities with Beneficial Conversion Features,” as those professional standards pertain to “Certain Convertible Instruments.” Accordingly, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their earliest date of redemption. The Company also records when necessary deemed dividends for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. ASC 815-40 provides that, among other things, generally, if an event is not within the entity’s control could or require net cash settlement, then the contract shall be classified as an asset or a liability.

Derivative Liabilities

The Company assessed the classification of its derivative financial instruments as of January 31, 2022 and April 30, 2021, which consist of convertible instruments and rights to shares of the Company’s common stock, and determined that such derivatives meet the criteria for liability classification under ASC 815.

RECENT ACCOUNTING PRONOUNCEMENTS

See Note A to the unaudited condensed consolidated financial statements for a description of recent accounting pronouncements, including the expected dates of adoption and estimated effects on our unaudited condensed consolidated financial statements, which is incorporated herein by reference.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures, as defined in Rule 13a-15(e) promulgated under the Exchange Act that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Principal Financial Officer, as appropriate to allow timely decisions regarding required disclosure. We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Principal Financial Officer, of the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of January 31, 2022. Based on the evaluation of these disclosure controls and procedures, and in light of the material weaknesses found in our internal controls, the Chief Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report were not effective.

A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control over financial reporting that is less severe than a material weakness, yet important enough to merit attention by those responsible for oversight of the company’s financial reporting. In our assessment of the effectiveness of internal control over financial reporting as of January 31, 2022, we determined that control deficiencies existed that constituted material weaknesses, as described below:

●	lack of documented policies and procedures;
●	we have no audit committee;
●	there is a risk of management override given that our officers have a high degree of involvement in our day-to-day operations.
●	there is no effective separation of duties, which includes monitoring controls, between the members of management.

Due to our size and nature, segregation of all conflicting duties may not always be possible and may not be economically feasible. As a result, we have not been able to take steps to improve our internal controls over financial. However, to the extent possible, we will implement procedures to assure that the initiation of transactions, the custody of assets and the recording of transactions will be performed by separate individuals. Management is currently evaluating what steps can be taken in order to address these material weaknesses.

Accordingly, we concluded that these control deficiencies resulted in a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis by our internal controls.

As a result of the material weaknesses described above, management has concluded that we did not maintain effective internal control over financial reporting as of January 31, 2022 based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

In light of these significant deficiencies, we performed additional analyses and procedures in order to conclude that our consolidated financial statements for the nine months ended January 31, 2022 included in this Quarterly Report on Form 10-Q were fairly stated in accordance with U.S. GAAP. Accordingly, management believes that despite our significant deficiency, our consolidated financial statements for the three months ended January 31, 2022 are fairly stated, in all material respects, in accordance with U.S. GAAP.

There was no change in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) that occurred during the fiscal quarter to which this report relates that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all error and fraud. Any control system, no matter how well designed and operated, is based upon certain assumptions and can provide only reasonable, not absolute, assurance that its objectives will be met. Further, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within the Company have been detected.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

As at January 31, 2022, we were not a party to any material pending legal proceeding except as stated below. From time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business.

On September 22, 2016, a motion for summary judgment in lieu of complaint was filed in the Supreme Court of The State of New York County of Kings, against the Company by a lender seeking: damages in the amount of $102,170.82 in principal and interest; accrued and unpaid interest thereupon in the amount from the date of filing to entry of judgment herein; lender’s reasonable attorney’s fees, costs, and expenses; and any such other relief as the Court deems just and proper. Plaintiff’s motion for summary judgment in lieu of complaint was denied on May 5, 2017. On August 22, 2018, Plaintiff brought a second motion seeking summary judgment on the issue of liability which was denied on March 14, 2019. The Court found that there existed issues of fact warranting a trial. The most recent appearance in this matter was scheduled for March 13, 2020 at which time the Court marked the case “adjourned without a date” due to the restrictions imposed on the Courts from the COVID-19 pandemic. These liabilities have been recorded in the unaudited condensed consolidated financial statements. While, there is no absolute guarantee in the outcome of this litigation, the Company believes the claim has no merit based on, among other things, a recent favorable decision by the New York State Court of Appeals relating to the affirmative defenses raised on the Company’s behalf in this litigation.

ITEM 1A. RISK FACTORS

We are subject to certain risks and uncertainties in our business operations including those which are described below. The risks and uncertainties described below are not the only risks we face. Additional risks and uncertainties not presently known or which are currently deemed immaterial may also impair our business operations. A description of factors that could materially affect our business, financial condition or operating results were included in Item 1A “Risk Factors” of our Form 10-K for the year ended April 30, 2021, and is incorporated herein by reference.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Each of the issuance and sale of securities described below was deemed to be exempt from registration under the Securities Act in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended, as transactions by an issuer not involving a public offering. No advertising or general solicitation was employed in offering the securities. Each purchaser is a sophisticated investor (as described in Rule 506(b) (2) (ii) of Regulation D) or an accredited investor (as defined in Rule 501 of Regulation D), and each received adequate information about the Company or had access to such information, through employment or other relationships, to such information.

Sales of Preferred Stock, Common Stock and Warrants:

During the nine months ended January 31, 2022 the Company:

Sold to four accredited investors 1,134,697 shares of common stock for cash of $70,000 and notes payable and accrued expenses settlement of $29,317.81.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 5. OTHER INFORMATION

Not applicable.

ITEM 6. EXHIBITS

The following exhibits are filed with this report:

Exhibit No.		Description
31.1*		Certification of Chief Executive Officer pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a)
31.2*		Certification of Principal Financial Officer pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a)
32.1*		Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350
101.INS*		Inline XBRL Instance Document
101.SCH*		Inline XBRL Taxonomy Extension Schema
101.CAL*		Inline XBRL Taxonomy Extension Calculation Linkbase
101.DEF*		Inline XBRL Taxonomy Extension Definition Linkbase
101.LAB*		Inline XBRL Taxonomy Extension Label Linkbase
101.PRE*		Inline XBRL Taxonomy Extension Presentation Linkbase
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

*Filed herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	SPARTA COMMERCIAL SERVICES, INC.

Date: March 17, 2022	By:	/s/ Anthony L. Havens
		Anthony L. Havens, Chief Executive Officer,
		Principal financial and accounting officer